The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk

Clinical Cancer Research

Volumn 12, Issue 4, 2006, Pages 1392-1394

  Langsenlehner, Uwe ^a   Yazdani Biuki, Babak ^a   Eder, Tanja ^a   Renner, Wilfried ^a   Wascher, Thomas C ^a   Paulweber, Bernhard ^b   Weitzer, Werner ^a   Samonigg, Hellmut ^a   Krippl, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; IMMUNE RESPONSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PREVALENCE; PRIORITY JOURNAL; PTGS2 GENE; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 33644758283     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2055     Document Type: Article

References (21)

1. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-60.
2. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437.
3. Soslow RA, Dannenberg AJ, Rush D, et al. Cox-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-45.
4. Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer 2004;4:428-33.
5. Pereg D, Lishner M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 2005;258:115-23.
6. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004; 31:22-9.
7. Bundred NJ, Barnes NL. Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer 2005;93 Suppl 1:S10-5.
8. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F. Association of a common polymorphism in the Cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 2004;25:229-35.
9. Cox DG, Pontes C, Guino E, et al. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 2004; 91:339-43.
10. Hu Z, Miao X, Ma H, et al. A common polymorphism in the 3′UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer 2005;48:11-7.
11. Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O. A genetic polymorphism in prostaglandin synthase 2 (8473, T→C) and the risk of lung cancer. Cancer Lett 2005;226:49-54.
12. Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003;106:468-71.
13. Esterbauer H, Schneitler C, Oberkofler H, et al. A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001;28:178-83.
14. Langsenlehner U, Krippl P, Renner W, et al. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 2005;90:113-5.
15. Cartharius K, Frech K, Grote K, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21: 2933-42.
16. Hofacker IL. Vienna RNA secondary structure server. Nucleic Acids Res 2003;31:3429-31.
17. Moraitis D, Du B, De Lorenzo MS, et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 2005;65: 664-70.
18. Cok SJ, Morrison AR. The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001;276:23179-85.
19. Wulfing P, Diallo R, Muller C, et al. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 2003;129:375-82.
20. Hamajima N, Takezaki T, Matsuo K, et al. Genotype frequencies of cyclooxygenease 2 (COX2) rare polymorphisms for Japanese with and without colorectal cancer. Asian Pac J Cancer Prev 2001;2:57-62.
21. Johnson ML, Seidman AD. Emerging targeted therapies for breast cancer. Oncology (Williston Park) 2005;19:611-8.